In utero exposure to tenofovir disoproxil fumarate does not impair growth and bone health in HIV-uninfected children born to HIV-infected mothers

Alessandra Viganò, Stefano Mora, Vania Giacomet, Sara Stucchi, Valeria Manfredini, Clara Gabiano, Filippo Salvini, Monica Cellini, Enrica Tamburrini, Maria Puzzovio, Gian Vincenzo Zuccotti

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Growth impairment and bone toxicity due to tenofovir disoproxil fumarate (TDF) fetal exposure has been described mainly in animals. We evaluated growth pattern and bone health in TDF-exposed HIV-uninfected children born to HIV-infected mothers, defined as seroreverters (SR). Methods: This was a multicentre observational cross-sectional cohort study enrolling 68 SR who were in utero exposed to an antiretroviral regimen including (TDF+) or not including (TDF-) tenofovir. Neonatal data and duration of antiretroviral exposure were recorded. At enrolment, anthropometric measures, tibial speed of sound (SOS) by quantitative ultrasound and several parameters of bone metabolism were assessed. Results: Gestational age and median in utero antiretroviral exposure were similar in subjects exposed to TDF (n=33) and those non-exposed (n=35). Age at enrolment was comparable in the two groups (TDF-exposed range 11.8-76.2 months and TDF non-exposed range 11.8-77.9 months). The incidence of low weight and length measurements (

Original languageEnglish
Pages (from-to)1259-1266
Number of pages8
JournalAntiviral Therapy
Volume16
Issue number8
DOIs
Publication statusPublished - 2011

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'In utero exposure to tenofovir disoproxil fumarate does not impair growth and bone health in HIV-uninfected children born to HIV-infected mothers'. Together they form a unique fingerprint.

Cite this